Asia accounts for 45 per cent of global breast cancer cases and 58 per cent of global cervical cancer deaths. New cervical cancer diagnoses in the region are projected to rise by 18.9 per cent by 2030, with deaths increasing by almost 25 per cent, while breast cancer diagnoses in the region are projected to rise by 20.9 per cent and deaths by 27.8 per cent in that same period. These rates are tracking higher than anticipated global rates of increase, sounding the alarm for policy makers, funders and civil society partners alike to act, as behind these alarming statistics lie the disheartening individual stories of women and their families.
In addition to grappling with the physical challenges of cancer, women also confront significant emotional, psychological, and financial strains. Because these diseases also carry the risk of stigma, they place a burden on women who are unable or unwilling to share their health challenges with others. Beyond these psychosocial impacts, women who must leave the workplace due to illness, or as caretakers, must contend with financial constraints resulting from lost income and compounded by catastrophic out of pocket payments on health care. Such scenarios can often pull families into cycles of poverty and impact future generations.
Investing in women’s cancer
Esta historia es de la edición BioSpectrum Asia Dec 2023 de BioSpectrum Asia.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición BioSpectrum Asia Dec 2023 de BioSpectrum Asia.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 8500 revistas y periódicos.
Ya eres suscriptor? Conectar
Australia invests $1.89B for health and medical research transformation
The government is investing in a once in a generation transformation of health and medical research in Australia.
NZ suggests new way to prevent rheumatic heart disease progression
A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.
WHO prequalifies Takeda's dengue vaccine
A new vaccine for dengue has received prequalification from the World Health Organization (WHO).
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.
HOYA Group to distribute AIassisted lesion detection device in US
Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.
Saudi Arabia pledges $500M to protect children from polio
At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.
How Thai Biotech is Thriving with Innovations
Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.
Why multi-use real estate is in demand for life sciences companies
India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.